HESH(301103)

Search documents
金城医药实控人收到行政处罚事先告知书;诺思格高级管理人员变动丨医药早参
Mei Ri Jing Ji Xin Wen· 2025-10-09 23:20
点评:赵叶青作为公司董事长,其个人严重违法行为必然会影响公司声誉和市场信心,暴露出公司在治 理和内控方面可能存在一些问题。这对于所有上市公司的"关键少数"都是一次严肃的警示。 NO.3 诺思格高级管理人员变动 每经记者|陈星 每经编辑|张海妮 丨 2025年10月10日 星期五 丨 NO.1 何氏眼科披露收购日本医道医疗株式会社进展 何氏眼科披露,近日,公司全资子公司广东横琴澳星启明国际医疗管理有限公司正式与株式会社医道メ ディカル及阴山泰成签署了《股份认购协议》。本次对株式会社医道メディカル投资事项涉及海外投 资,资金的汇出尚需经过国内的发改委、商务主管部门、外汇主管部门等境内主管机关以及日本相关政 府部门的批准或备案。 点评:何氏眼科跨境投资医道メディカル,是眼科医疗国际化布局的关键一步。交易需中日两国多部门 审批,凸显跨境医疗投资的高门槛与合规复杂性。 NO.2 金城医药实际控制人收到行政处罚事先告知书 近日,金城医药实际控制人、董事长赵叶青等人因违反证券法相关规定,被处以300万元罚款。其中, 赵叶青承担150万元,并被实施4年市场禁入措施。 免责声明:本文内容与数据仅供参考,不构成投资建议,使用前请 ...
何氏眼科(301103) - 关于使用部分超募资金注资全资子公司收购株式会社医道メディカル70.65%股权的进展公告
2025-10-09 07:58
关于使用部分超募资金注资全资子公司收购 证券代码:301103 证券简称:何氏眼科 公告编号:2025-038 辽宁何氏眼科医院集团股份有限公司 三、风险提示 1、本次对株式会社医道メディカル公司投资事项涉及海外投资,资金的汇出 尚需经过国内的发改委、商务主管部门、外汇主管部门等境内主管机关以及日本 相关政府部门的批准或备案手续,本次投资能否通过上述审批或备案程序以及通 过的时间存在不确定性。 株式会社医道メディカル 70.65%股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 一、对外投资概述 辽宁何氏眼科医院集团股份有限公司(以下简称"公司")于 2025 年 8 月 26 日召开第三届董事会第十一次会议、2025 年 9 月 15 召开 2025 年第一次临时股 东大会,审议通过了《关于使用部分超募资金注资全资子公司收购株式会社医道 メディカル 70.65%股权的议案》。为进一步推进和提升公司国际化战略布局能力, 推动公司在医疗健康产业的创新发展,公司拟使用超募资金 4,000 万元人民币对 公司全资子公司广东横琴澳星启明国际医疗管理有限公 ...
何氏眼科涨2.14%,成交额2400.67万元,主力资金净流出174.89万元
Xin Lang Cai Jing· 2025-09-30 06:57
Company Overview - He Eye Hospital Group, established on October 15, 2009, is located in Shenyang, Liaoning Province, and was listed on March 22, 2022 [1] - The company primarily provides specialized ophthalmic diagnosis and treatment services, with revenue composition as follows: Vision services 30.24%, Refractive surgery correction services 24.16%, Non-surgical treatment 20.02%, Cataract diagnosis and treatment services 13.68%, Vitreoretinal diagnosis and treatment services 8.09%, Other ophthalmic diagnosis and treatment services 3.20%, Other business income 0.61% [1] Financial Performance - As of June 30, 2025, He Eye Hospital reported operating revenue of 560 million yuan, a year-on-year decrease of 4.22%, while net profit attributable to shareholders was 44.32 million yuan, reflecting a year-on-year increase of 84.19% [2] - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] Stock Performance - As of September 30, the stock price of He Eye Hospital increased by 2.14% to 21.03 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Year-to-date, the stock price has risen by 5.29%, with a 1.69% increase over the last five trading days, but a decline of 3.93% over the last 20 days and 3.53% over the last 60 days [1] - The number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3]
何氏眼科:公司主要是通过参与产业投资基金的方式进行相关布局
Zheng Quan Ri Bao Wang· 2025-09-26 08:12
Core Viewpoint - He Eye Hospital (301103) is primarily engaging in industry investment funds rather than direct research and production activities [1] Group 1: Company Activities - The company participates as a limited partner in the establishment of the Zhaohua (Guizhou) Health Technology Industry Development Fund, which focuses on eye health [1] - The fund primarily invests in new-generation medical health, dietary nutrition, and synthetic biology sectors [1] Group 2: Future Disclosures - The company will strictly adhere to information disclosure requirements and announce any significant developments in a timely manner [1]
何氏眼科9月25日获融资买入436.50万元,融资余额6575.96万元
Xin Lang Cai Jing· 2025-09-26 01:36
分红方面,何氏眼科A股上市后累计派现3.48亿元。近三年,累计派现2.75亿元。 机构持仓方面,截止2025年6月30日,何氏眼科十大流通股东中,融通健康产业灵活配置混合A/B (000727)位居第六大流通股东,持股279.47万股,相比上期减少175.84万股。 责任编辑:小浪快报 资料显示,辽宁何氏眼科医院集团股份有限公司位于辽宁省沈阳市皇姑区黄河南大街118号甲泰和国际 大厦15层,成立日期2009年10月15日,上市日期2022年3月22日,公司主营业务涉及面向眼病患者提供 眼科专科诊疗服务和视光服务。主营业务收入构成为:视光服务30.24%,屈光不正手术矫正服务 24.16%,非手术治疗20.02%,白内障诊疗服务13.68%,玻璃体视网膜诊疗服务8.09%,其他眼病诊疗服 务3.20%,其他业务收入0.61%。 截至6月30日,何氏眼科股东户数1.08万,较上期增加15.03%;人均流通股7684股,较上期减少 13.07%。2025年1月-6月,何氏眼科实现营业收入5.60亿元,同比减少4.22%;归母净利润4432.46万元, 同比增长84.19%。 9月25日,何氏眼科跌1.67%,成交额 ...
何氏眼科分享眼健康生态共建经验
Zheng Quan Ri Bao Wang· 2025-09-24 12:44
Group 1 - The second International Civil Society Conference on Global Development Initiatives was held in Hohhot, co-hosted by the China International Exchange Promotion Association and the Inner Mongolia Autonomous Region Government, with He Eye Hospital Group invited to participate [1] - He Eye Hospital has been focusing on eye health for 30 years, leveraging innovative technology to build a comprehensive ecosystem in the eye health industry, aiming to create the "He Smart Bright City" [1] - He Eye Hospital is a member of the World Association of Eye Hospitals (WAEH) and actively participates in international training programs and foreign aid medical projects [1] Group 2 - Recently, He Eye Hospital has signed cooperation agreements with civil organizations from Malaysia, Pakistan, and Ethiopia to expand its international collaboration in public health within the eye health sector [2] - During the conference, He Eye Hospital signed a cooperation agreement with the Zambian Ministry of Health to enhance eye health services in Zambia through talent training, technology sharing, and innovative models [2] - He Eye Hospital aims to strengthen international cooperation in public health by sharing technology, exchanging talents, and providing public welfare services, contributing to the construction of a community with a shared future for mankind [2]
何氏眼科:眼健康全产业链生态助力打造国际合作“朋友圈”
Zhong Zheng Wang· 2025-09-24 12:18
作为世界眼科医院协会(WAEH)成员,多年来,何氏眼科发挥国际眼科基金会(OF)国际眼科医师培训机 构和国家卫健委防盲治盲培训基地平台作用,主动承担国家援外医疗项目,为多个援外培训项目提供支 持。通过学术交流、技术交流、人才交流等方式,何氏眼科输出高效率、可复制、可持续的中国眼健康 模式,为亚洲、非洲和拉丁美洲的发展中国家培养基层医生和眼健康管理人员,推动全球眼健康事业可 持续发展。 近日,何氏眼科与马来西亚、巴基斯坦、埃塞俄比亚等国家民间组织签署合作协议,进一步拓展眼健康 领域公共卫生国际合作"朋友圈"。大会期间,何氏眼科与赞比亚卫生部代表签订合作协议。何氏眼科将 通过人才培养、技术分享和防盲模式搭建等方式,借助大数据、人工智能等创新技术,推进赞比亚眼健 康事业高质量发展,助力当地眼健康服务能力提升。 中证报中证网讯(王珞)日前,第二届国际民间社会共同落实全球发展倡议交流大会在内蒙古自治区呼和 浩特市举行,何氏眼科(301103)受邀参加。公司国际防盲合作实践成果亮相国际舞台,受到中外嘉宾 广泛关注。何氏眼科相关负责人表示,公司将以此次大会为契机,在公共卫生领域强化与各国民间机构 交流合作,通过技术共享、人 ...
辽宁何氏眼科医院集团股份有限公司第三届董事会第十二次会议决议公告
Shang Hai Zheng Quan Bao· 2025-09-23 09:07
Group 1 - The company held its 12th meeting of the third board of directors on September 19, 2025, with all seven directors present, and the meeting was deemed legal and effective [2][3][4] - The board approved the draft of the 2025 Restricted Stock Incentive Plan to attract and retain talented management and align interests among shareholders, the company, and key personnel [3][5][6] - The board also approved the management measures for the implementation of the 2025 Restricted Stock Incentive Plan to ensure its smooth operation and performance [5][6][7] Group 2 - The company proposed to use up to RMB 680 million of idle raised funds and up to RMB 620 million of its own funds for cash management, aiming to improve fund utilization efficiency without affecting normal operations [14][21][24] - The cash management will involve purchasing low-risk financial products, ensuring that the funds remain secure and liquid [26][28][30] - The board's decision on cash management is subject to approval at the upcoming second extraordinary general meeting of shareholders on October 20, 2025 [16][20][45] Group 3 - The company will hold its second extraordinary general meeting of shareholders on October 20, 2025, with provisions for both on-site and online voting [16][46][49] - The meeting will require a two-thirds majority vote for special resolutions related to the restricted stock incentive plan [49] - Shareholders must register for the meeting and can participate either in person or through online voting [48][50][51]
何氏眼科跌2.02%,成交额1599.53万元,主力资金净流入87.21万元
Xin Lang Cai Jing· 2025-09-23 02:27
Core Viewpoint - He Eye Hospital's stock price has experienced fluctuations, with a year-to-date increase of 2.14% but a significant decline in recent trading periods, indicating potential volatility in investor sentiment [2]. Company Overview - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, is located in Shenyang, Liaoning Province. The company specializes in providing ophthalmic specialty diagnosis and treatment services [2]. - The revenue composition of He Eye Hospital includes: Vision services (30.24%), Refractive surgery correction services (24.16%), Non-surgical treatments (20.02%), Cataract diagnosis and treatment services (13.68%), Vitreoretinal diagnosis and treatment services (8.09%), Other ophthalmic diagnosis and treatment services (3.20%), and Other business income (0.61%) [2]. Financial Performance - As of June 30, 2025, He Eye Hospital reported a revenue of 560 million yuan, a year-on-year decrease of 4.22%. However, the net profit attributable to shareholders was 44.32 million yuan, reflecting a significant year-on-year increase of 84.19% [2]. - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for He Eye Hospital was 10,800, an increase of 15.03% from the previous period. The average circulating shares per person decreased by 13.07% to 7,684 shares [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B fund held 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3].
何氏眼科(301103.SZ):拟推637万股限制性股票激励计划
Ge Long Hui A P P· 2025-09-22 12:10
Core Points - He Eye Hospital (301103.SZ) announced a restricted stock incentive plan for 2025, proposing to grant 6.37 million restricted shares, which accounts for approximately 4.03% of the company's total share capital of 158.03 million shares at the time of the announcement [1] - The number of initial grant recipients under this incentive plan will not exceed 240 individuals [1] - The grant price for the initially awarded restricted shares is set at 13 yuan per share, with the same price applicable for any reserved restricted shares [1]